更新版 1-美国 FDA 批准<a href="https://laohu8.com/S/0O59.UK">赛诺菲</a>治疗罕见血液病的药物在第2-4段中增加了细节
路透8月29日 - 赛诺菲公司周五 表示，美国食品和药物管理局已经批准了该公司用于治疗一种血液疾病的SASY.PA药物，这表明这家法国制药商押注37亿美元的治疗方案可能开始获得回报。
该药物的批准有助于赛诺菲在更大范围内推动其成为罕见病和免疫学药物领域的强势企业，因为赛诺菲希望在其最畅销的湿疹治疗药物Dupixent之外推动增长，该药物是赛诺菲与Regeneron Pharmaceuticals REGN.O公司合作开发的。
赛诺菲在 2020 年通过收购 Principia Biopharma 公司获得了口服药物 rilzabrutinib。Leerink分析师预计，该疗法的销售峰值将达到20亿至50亿美元。
Rilzabrutinib将以Wayrilz的品牌名称销售，它已获准用于对先前治疗无效的持续性或慢性免疫性血小板减少症成人患者$(ITP)$。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
At the request of the copyright holder, you need to log in to view this content
LOGIN / SIGN UPDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.